Prenuvo Review: Scan Cost, Membership Terms and MRI Evidence

The short verdict

Prenuvo sells elective MRI screening and imaging memberships. Its whole-body scan is listed at $2,499 in the United States, but the similarly priced Comprehensive membership carries different services and renewal obligations. The important decision is twofold: whether broad screening is appropriate for you, and which purchase agreement you are accepting. More imaging information can be useful; it can also produce uncertain findings that require another appointment and another bill.

This is a review of published services, terms and research, rather than a firsthand scan report. We assess the screening product here; our longevity clinic rankings use a separate rubric for provider programs.

What the published prices buy

The US offers below were checked October 15, 2026. Membership blood panels depend on location. Executive pricing varies by clinic; obtain a location-specific total rather than treating the starting figure as universal. Financing installments are a way to pay a purchase price, not evidence of a cancel-anytime monthly service.¹

The practical comparison is coverage versus commitment. Ask for the exact imaging regions, laboratory panel, review appointments and add-ons in your confirmation. Two offers with the same headline price can have very different consequences if you want only one screening visit. Compare that structure with the broader concierge services in our Fountain Life review, rather than assuming a scan and a year of clinical care are interchangeable.

The membership terms matter as much as the scan

Prenuvo's terms describe a 12-month membership that automatically renews. The next fee can be charged about two days before expiry; cancellation must arrive at least three business days before the term ends to avoid that renewal. Cancellation is available through the account or by email. A full membership refund is specified within three days of purchase and before the first medical services; outside that window the published terms generally deny refunds, subject to applicable law. The terms also say fees exclude applicable taxes and require advance renewal notification.²

Those membership provisions should not be substituted for the appointment policy on a standalone booking. Before paying, save the agreement for the exact product you selected. Confirm what happens if you reschedule, cannot complete the exam, or need further imaging. A promotional discount does not answer those questions.

For budgeting, separate three decisions: the screening purchase, a possible repeat purchase, and any diagnostic care prompted by a finding. Ask who arranges the latter and which fees fall outside the quoted package. Do not assume a results discussion includes specialist treatment or a biopsy.

What MRI can do, and what a clear scan cannot promise

Prenuvo says its screening scans use neither ionizing radiation nor intravenous contrast. Its FAQ currently limits screening to adults 18 and older and requires payment when booking. It also explicitly says the exam does not replace recommended targeted screening. Eligibility still needs the clinic's MRI safety review; disclose implants and any relevant medical history before scheduling.³

A broad MRI and a targeted diagnostic examination answer different questions. New symptoms deserve clinical assessment and an appropriate workup, even if a previous screening report was reassuring. Similarly, a scan should not displace age- and risk-appropriate cancer screening. The useful question is what information this particular exam adds to an existing care plan, and what you would do differently because of it.

What Prenuvo's cancer-detection research shows

Prenuvo reproduces a 2025 AACR conference abstract describing a retrospective, single-center case series of 1,011 people. Eighteen percent had specific symptoms as their reason for scanning, so this was not an entirely asymptomatic population. Reported cancer detection was 2.2%; tissue sampling followed in 50 cases. Two breast cancers were reported as false negatives. Follow-up relied partly on patient reports, and the authors identified incomplete medical records as a limitation.⁴

That is evidence that scans can lead to cancer diagnoses. It is not a randomized comparison showing fewer deaths, fewer late-stage cancers over time, or better overall health than usual care. A conference abstract also provides less methodological detail than a full research report. Neither a detection percentage nor a negative predictive value should be read as your personal probability of being free of every disease.

Incidental findings are the central trade-off

Our MRI evidence comparison examines incidental-finding research in apparently healthy adults. Its central limitation applies here too: results from mixed screening protocols are not a forecast of an individual Prenuvo customer's result. Findings and follow-up vary by the population, scan protocol and threshold for flagging an observation.

An incidental finding is an unexpected observation. It may be important, harmless, or unresolved. A false positive is a suspected problem subsequently shown not to be present. Overdiagnosis means detecting a real condition that would never have harmed the person. These categories overlap in the screening debate, but they are not interchangeable, and counting every harmless cyst as a false cancer alarm would mislead readers.

The American College of Radiology's published statement says evidence is insufficient to recommend total-body screening for people without symptoms, risk factors or a suggestive family history. It highlights uncertain benefit and the potential for additional testing, procedures and expense.⁵ That judgment concerns broad screening in low-risk people; it does not dismiss clinically indicated MRI.

Who should pause before booking

Pause if you are seeking an all-clear for symptoms, expect the package to replace routine preventive care, or cannot comfortably absorb follow-up costs. Also pause if an uncertain result would create a strong urge to pursue every possible test: a plan for handling ambiguity belongs before the scan, not after it.

For someone considering elective screening despite those limitations, a useful discussion with an independent clinician covers baseline risk, existing screening, which findings would change treatment, and how an indeterminate result would be followed. The Fountain Life versus Human Longevity comparison explores the same follow-up questions in higher-cost programs.

Our assessment

Prenuvo makes its offer more inspectable than a service that requires a sales call for every number. The purchase still needs careful reading: the lower-priced Focused scan has narrower coverage, the membership renews, and a broader view of anatomy is not itself proof of better long-term outcomes. The evidence supports a real imaging service with meaningful limitations. Whether the information is worth the cost depends on risk, the care already in place, and willingness to manage uncertain findings.